An update on the safety and tolerability of pimecrolimus cream 1%: Evidence from clinical trials and post-marketing surveillance

Dermatology

Volumn 215, Issue SUPPL. 1, 2007, Pages 27-44

  Langley, Richard G B ^a   Luger, Thomas A ^b   Cork, Michael J ^c   Schneider, Dirk ^d   Paul, Carle ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Eczema; Elidel; Pimecrolimus cream 1

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE ACETATE; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ABDOMINAL PAIN; ABSCESS; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; ANGIONEUROTIC EDEMA; APPLICATION SITE BURNING; APPLICATION SITE DISCOLORATION; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ASTHMA; ATOPIC DERMATITIS; B CELL LYMPHOMA; BACKACHE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLADDER CANCER; BLEPHARITIS; BODY SURFACE; BREAST CANCER; BRONCHITIS; CANCER RISK; CELLULITIS; CHICKENPOX; CLINICAL TRIAL; CONJUNCTIVITIS; CONNECTIVE TISSUE DISEASE; COUGHING; DERMATITIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; EAR INFECTION; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; FOLLICULITIS; FOLLOW UP; FURUNCULOSIS; GASTROENTERITIS; HEPATOBLASTOMA; HERPES SIMPLEX; HERPES ZOSTER; HODGKIN DISEASE; HORDEOLUM; HOT FLUSH; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IMPETIGO; INCIDENCE; INFECTION RISK; INFLUENZA; INSOMNIA; JUVENILE MELANOMA; LEUKEMIA; LONG TERM CARE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MIGRAINE; MOLLUSCUM CONTAGIOSUM; MUSCULOSKELETAL DISEASE; MYALGIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NOSE CONGESTION; NOSE INFECTION; OTITIS MEDIA; PARONYCHIA; PEDIATRICS; PHARYNGITIS; PITYRIASIS ROSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIASIS; RECURRENT CANCER; REVIEW; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; RISK ASSESSMENT; RISK FACTOR; SINUSITIS; SKIN ATROPHY; SKIN CARCINOMA; SKIN INFECTION; SKIN PAPILLOMA; SORE THROAT; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; T CELL LYMPHOMA; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TONSILLITIS; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERRUCA VULGARIS; VIRUS INFECTION; VOMITING; WOUND INFECTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CALCINEURIN; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; PRODUCT SURVEILLANCE, POSTMARKETING; SKIN ABSORPTION; SKIN DISEASES, INFECTIOUS; TACROLIMUS;

EID: 37349125328     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102118     Document Type: Review

References (80)

1. Leung DY, Bieber T: Atopic dermatitis. Lancet 2003;361:151-160.
2. Finlay AY: Quality of life in atopic dermatitis. J Am Acad Dermatol 2001;45:S64-S66.
3. Fischer G: Compliance problems in pediatric atopic eczema. Aust J Dermatol 1996;37:10-13.
4. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-936.
5. Fukaya M: Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000;201:242-245.
6. Hepburn D, Yohn JJ, Weston WI: Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994;9:225-254.
7. Hanifin JM, Tofte SJ: Update of therapy of atopic dermatitis. J Allergy Clin Immunol 1999;104:S123-S125.
8. Raimer SS: Managing pediatric atopic dermatitis. Clin Pediatr 2000;39:1-14.
9. Abeck D, Strom K: Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-46.
10. Hill CJ, Rosenberg A, Jr: Adverse effects from topical corticosteroids. Cutis 1978;21:624-628.
11. Stoppolino G, Prisco F, Santinelli R, Sicuranza G, Giordano C: Potential hazards of topical steroid therapy. Am J Dis Child 1983;137:1130-1131.
12. Lewis-Jones S: Atopic dermatitis in childhood. Hosp Med 2001;62:136-143.
13. Queille C, Pommarede R, Saurat JH: Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984;1:246-253.
14. Turpeinen M, Salo OP, Leisti S: Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-484.
15. Turpeinem M: Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988;118:517-522.
16. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ: Adverse effects of topical glucocorticoids. J Am Acad Dermatol 2006;54:1-15.
17. Bos JD: Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003;13:455-461.
18. Iskedjian M, Piwko C, Shear NH, Langley RGB, Einarson TR: Topical calcineurin inhibitors in the treatment of atopic dermatitis. A meta-analysis of current evidence. Am J Clin Dermatol 2004;5:267-279.
19. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder J-F, Thestrup-Pedersen K (European Working Group on Atopic Dermatitis): The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004;151(suppl 70):3-27.
20. Kapp A, Allen BR, Reitamo S: Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatol Treat 2003;14(suppl 1):5-16.
21. Simpson D, Noble S: Tacrolimus ointment: A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005;65:827-858.
22. Wellington K, Jarvis B: Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-840.
23. Graham-Brown RAC, Grassberger M: Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003;57:319-327.
24. Eichenfield LF, Beck L: Elidel (pimecrolimus) cream 1% - a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-1165.
25. Wolff K, Stuetz A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004;5:643-655.
26. Grassberger M, Steinhoff M, Schneider D, Luger TA: Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004;13:721-730.
27. Billich A, Aschauer H, Aszódi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through the skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
28. Hultsch T, Kapp A, Spergel J: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174-187.
29. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y: Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006;117:e118-e128.
30. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
31. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-787.
32. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin M-E, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-973.
33. Lakhanpaul M, Davies T, Allen BR, Schneider D: Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006;15:138-141.
34. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Creig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-887.
35. Meingassner JG, Heinrich A, Stuetz A, Billich A: Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 2005;14:752-757.
36. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, Paul CF: Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005;53:602-609.
37. Paller AS, Lebwohl M, Fleischer AB, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski CJ; US/Canada Tacrolimus Ointment Study Group: Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol 2005;52:810-822.
38. Kapp A, Papp K, Bingham A, Foelster-Holst R, Ortonne J-P, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y, Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-284.
39. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y; Flare Reduction in Eczema with Elidel (children) multicenter investigator study group: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1-8.
40. Meurer M, Foelster-Holst R, Wozel G, Weidinger G, Juenger M, Braeutigam M, CASMDE-01 Study Group: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002;205:271-277.
41. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M, CASM-DE-01 Study Group: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
42. Luger TA, Lahfa M, Foelster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatol Treat 2004;15:169-178.
43. Papp KA, Werfel T, Foelster-Holst R, Ortonne J-P, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C: Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52: 240-246.
44. Zhang J, Yu X: A SAS® program for estimating incidence density for cohort studies with multiple follow-ups. http://www.nesug.org/html/Proceedings/ nesug03/ph/ph008.pdf.
45. Washenik K, Cherill R, Felser J, Abrams B: Pimecrolimus (SDZ ASM 981) cream: A similarly low incidence of application site burning compared with vehicle in pediatric patients. 60th Annual Meeting of the American Academy of Dermatology, New Orleans (LA), 2002. Poster No. P118. Poster Abstracts Book available online at: http://www.aad.org/NR/rdonlyres/B77B2CFB-60B2-4973-8D02- E2CB5BC48F4B/0/AM02abstract. pdf.
46. Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D, Stiller M, Tschen E, Chon K, Wisseh S, Abrams B: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004;51:515-525.
47. Luebbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003;4:641-654.
48. David TJ, Longson M: Herpes simplex infections in atopic eczema. Arch Dis Child 1985;60:338-343.
49. Bonifazi E, Garofalo L, Pisani V, Meneghini CL: Role of some infectious agents in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985;114:98-100.
50. David TJ, Cambridge GC: Bacterial infections in atopic eczema. Arch Dis Child 1986;61:20-23.
51. Brown CA: Common eye problems in infants and children. Practitioner 1977;219:53-58.
52. Rodriguez-Rosado R, Soriano V, Dona C, Gonzalez-Lahoz J: Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antivir Ther 1998;3:229-231.
53. Varon NF, Alangaden GJ: Emerging trends in infections among renal transplant recipients. Expert Rev Anti Infect Ther 2004;2:95-109.
54. Chiu LM, Domagala BM, Park JM: Management of opportunistic infections in solid-organ transplantation. Prog Transplant 2004;14:114-129.
55. Queille-Roussel C, Paul C, Duteil C, Lefebvre M-C, Rapatz G, Zagula M, Ortonne JP: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol 2001;144:507-513.
56. Haapasaari KM, Risteli J, Koivukangas V, Oikarinen A: Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol 1995;75:269-271.
57. Haapasaari KM, Risteli J, Karvonen J, Oikarinen A: Effect of hydrocortisone, methylprednisolone acetonate and mometasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol 1997;10:261-264.
58. Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K: The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol 1998;139:1106-1110.
59. Sheu HM, Lee JYY, Chai CY, Kuo K: Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997;136:884-890.
60. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T: Corticosteroid-induced atrophy and barrier impairment measured by noninvasive methods in human skin. Skin Res Technol 2001;7:73-77.
61. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456-464.
62. Danchin MH, Rogers S, Selvaraj G, Kelpie L, Rankin P, Vorich R, Howson M, Carlin JB, Curtis N, Nolan TM, Carapetis JR: The burden of group A streptococcal pharyngitis in Melbourne families. Indian J Med Res 2004;119:144-147.
63. Milingou M, Antille C, Sorg O, Saurat J-H, Luebbe J: Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol 2004;140:1542-1544.
64. Novartis: Elidel® (pimecrolimus) Cream 1%. For dermatologic use only. Not for ophthalmic use. Rx only. Prescribing information. Revised January 2006. http://www.pharma.us.novartis.com/product/pi/pdf/elidel.pdf.
65. Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML: Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999;68:997-1003.
66. Ganshow R, Schulz T, Meyer T, Broering DC, Burdelski M: Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr 2004;38:198-203.
67. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS: Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol 2000;143:513-519.
68. Papp KA, Breuer K, Meurer M, Ortonne J-P, Potter PC, de Prost Y, Davidson MJ, Barbier N, Goertz HP, Paul C: Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005;52:247-253.
69. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Nonmelanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001;85:683-686.
70. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-711.
71. Fonacier L, Spergel J, Charlesworth EN, Weldon D, Beltrani V, Bernhisel-Broadbent J, Boguniewicz M, Leung DY; American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology: Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005;115:1249-1253.
72. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, Giannetti A, Hawk J, Hoenigsmann H, Kemeny L, Luger T, Meurer M, Murphy G, Peserico A, Ranki A, Reunala T, Saurat J, Sterry W, van de Kerkhof P: Review of the potential photo-carcinogenicity of topical calcineurin inhibitors. Position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005;19:663-671.
73. Alekseev S, Kool H, Rebel H, Fousteri M, Moser J, Backendorf C, de Gruijl FR, Vrieling H, Mullenders LH: Enhanced DDB2 expression protects mice from carcinogenic effects of chronic UV-B irradiation. Cancer Res 2005;65:10298-10306.
74. Tran C, Luebbe J, Sorg O, Doelker L, Carraux P, Antille C, Grand D, Leemans E, Kaya G, Saurat JH: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211:341-347.
75. Jacobs J, Avalos J, Brown P, Wilkin J: Does photosensitivity predict photocarcinogenicity? Int J Toxicol 1999;18:191-198.
76. Ryffel B: The carcinogenicity of ciclosporin. Toxicology 1992;73:1-22.
77. Biemer JJ: Malignant lymphomas associated with immunodeficiency states. Ann Clin Lab Sci 1990;20:175-191.
78. Ormerod AD: Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005;153:701-705.
79. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Fast Stats: Non-Hodgkin Lymphoma. Age-adjusted incidence rates and 95% confidence intervals. SEER 13 Registries for 1998-2002. http://seer.cancer.gov/ faststats/sites.php?stat=Incidence&site=Non-Hodgkin+Lymphoma&x=10&y= 16.
80. Food and Drug Administration: FDA News. FDA approves updated labeling with box warning and medication guide for two eczema drugs, Elidel and Protopic. http://www.fda.gov/bbs/topics/news/2006/NEW01299.html.